表紙
市場調查報告書
商品編碼
1056682

納米粒子(脂質納米粒子/金屬納米粒子)市場的合同製造:按公司規模、製造的納米粒子類型和運營規模(臨床前、臨床、商業)

Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size, Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial),

出版日期: | 出版商: Roots Analysis | 英文 265 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

大多數提供與納米粒子相關的現成和定制服務的領先製藥公司的總部都在美國。此外,開發商對使用合同製造服務的興趣日益濃厚,預計未來將為此類服務提供商提供有利的市場機會。

最近,疫苗開發商和 CMO 簽署了許多協議,以滿足開發 COVID-19 疫苗對基於納米顆粒的解決方案的迫切需求。鑑於使用納米粒子改善藥物性能的好處,預計未來幾年合同製造市場對高質量納米粒子的需求可能會顯著推動增長。

本報告調查全球納米粒子合同製造市場,並提供有關納米粒子概述、預測和機會、分類分析、公司概況等方面的信息。

示例

目錄

第一章前言

第2章執行摘要

第三章介紹

  • 章節概述
  • 納米粒子介紹
    • 納米粒子型
  • 與納米粒子生產相關的問題
  • 合同製造概述
  • 一般外包納米粒子製造業務
  • 納米粒子製造業務外包的好處
  • 選擇代工合作夥伴時的重要注意事項
  • 未來展望

第四章市場情況

  • 章節概述
  • 納米粒子合同製造商:整體市場情況
    • 成立年份分析
    • 按公司規模分析
    • 按總部位置分析
    • 按組織類型分析
    • 按製造的納米粒子類型分析
    • 按製造設施的位置分析
    • 按經營規模分析
    • 按最終用戶類型分析
    • 按提供的服務類型分析
    • 質量認證分析
    • 監管分析
    • 主要納米粒子合同製造商:按製造設施數量分析

第 5 章主要見解

  • 章節概述
  • 按公司規模和組織類型分析
  • 按公司規模和製造納米粒子類型的分析
  • 按公司規模和經營規模分析
  • 按總部所在地分析(按國家/地區)
  • 按公司規模、製造納米粒子類型、製造設施數量、提供的服務數量進行分析
  • 按組織類型、製造納米顆粒類型、運營規模、最終用戶類型、提供的服務類型進行分析

第6章公司競爭分析

  • 章節概述
  • 先決條件和關鍵參數
  • 調查方法
  • 服務實力基準
  • 合作活動的基準
  • 納米粒子合同製造商:公司競爭分析

第 7 章公司簡介

  • 章節概述
  • Ardena
    • 企業概要
    • 最近動向與未來展望
  • Curia
  • Corden Pharma
  • Evonik
  • LSNE Contract Manufacturing
  • Polymun
  • TechNanoIndia

第 8 章夥伴關係和合作

  • 章節概述
  • 合作模式
  • 納米粒子的合同製造:夥伴關係與協作

第9章外包:GO/NO-GO框架

  • 章節概述
  • 假設和參數定義
  • 基於納米粒子的治療開發人員外包:Go/No-Go 框架
  • 外包:Go/No-Go 框架
  • 結論

第 10 章市場預測和機會分析

  • 章節概述
  • 預測性調查方法及主要前提條件
  • 全球納米粒子合同製造市場(2021-2035)
  • 納米粒子合同製造市場:按公司規模分佈(2021 年、2035 年)
    • 微型企業(2021-2035)
    • 小型企業 (2021-2035)
    • 中型企業(2021-2035)
    • 大公司 (2021-2035)
  • 納米粒子合同製造市場:按製造納米粒子類型分佈(2021 年、2035 年)
    • 脂質納米粒子(2021-2035)
    • 金屬納米粒子 (2021-2035)
  • 納米粒子合同製造市場:按運營規模分佈(2021 年、2035 年)
    • 臨床前 (2021-2035)
    • 臨床(2021-2035)
    • 商業 (2021-2035)
  • 納米粒子合同製造市場:按最終用戶類型分佈(2021 年、2035 年)
    • 教育機構(2021-2035)
    • 製藥公司(2021-2035)
    • 研究院(2021-2035)
    • 其他 (2021-2035)
  • 納米粒子合同製造市場:按地區分佈(2021 年、2035 年)
    • 北美 (2021-2035)
    • 歐洲 (2021-2035)
    • 亞洲 (2021-2035)
    • 中東/北非 (2021-2035)
    • 拉丁美洲 (2021-2035)
    • 其他領域 (2021-2035)
  • 納米粒子合同製造市場:納米粒子類型和地區分佈(2021 年、2035 年)
    • 北美脂質納米顆粒的納米顆粒合同製造市場(2021-2035 年)
    • 歐洲脂質納米粒子的納米粒子合同製造市場(2021-2035 年)
    • 脂質納米顆粒的納米顆粒合同製造市場,亞洲(2021-2035 年)
    • 中東/北非脂質納米粒子納米粒子的合同製造市場(2021-2035 年)
    • 拉丁美洲脂質納米顆粒的納米顆粒合同製造市場(2021-2035 年)
    • 脂質納米顆粒的納米顆粒合同製造市場,其他地區(2021-2035)
    • 北美金屬納米粒子的納米粒子合同製造市場(2021-2035 年)
    • 歐洲金屬納米粒子的納米粒子合同製造市場(2021-2035 年)
    • 亞洲金屬納米粒子的納米粒子合同製造市場(2021-2035 年)
    • 金屬納米粒子的納米粒子合同製造市場,中東/北非(2021-2035)
    • 拉丁美洲金屬納米粒子的納米粒子合同製造市場(2021-2035 年)
    • 金屬納米粒子的納米粒子合同製造市場,其他地區(2021-2035)

第11章結論

第 12 章執行洞察力

第十三章附錄一:聚合數據

第十四章附錄二:公司和組織名單

目錄

Title:
Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles)
Market by Company Size, Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User, and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA), Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035.

Example Insights:

Overview

"Majority of big pharma players that offer a wide range off the shelf products and custom services associated with nanoparticles are headquartered in the US. Further, given the rising interest of developer companies to avail contract manufacturing services, such service providers are likely to witness lucrative market opportunities in the foreseen future". - CEO, Europe based Small Sized Company.

Over the past few decades, the pharmaceutical industry has witnessed significant growth, as also evident from the continuously growing pipeline of drug candidates that have been marketed or are being evaluated across several development stages. However, a recent study published in the journal of Analytical and Pharmaceutical Research has highlighted that around 90% of the candidates in the current preclinical development pipeline and more than 40% of the marketed pharmacological products are associated with concerns related to solubility / permeability. Further, it was observed that a pharmacological product became 10% less vigorous, each time, when mixed with another product, due to drug incompatibility.Therefore, players engaged in this domain are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, the use of nanoparticles has garnered the attention of many drug developers. In fact, the novel vaccines developed to treat COVID-19 are enclosed within a layer of lipid nanoparticles; these molecules assist the delivery of active ingredients to the required site of action. Moreover, many drug developers are using lipid / metal nanoparticles to re-formulate existing product candidates in order to further improve their bioavailability / biocompatibility. However, for some of the nanoparticles having medical applications, the associated manufacturing processes are highly complex, capital-intensive and fraught with multiple challenges, such as need for specialized expertise (especially in case of lipid nanoparticles) , lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Considering the routine operations-related and technical challenges, an increased number of pharmaceutical companies have demonstrated the preferences to outsource their respective nanoparticle production operations to specialized service providers.

There are numerous benefits of engaging contract development and manufacturing (CDMO) / contract manufacturing organizations (CMO) for nanoparticle manufacturing; for instance, contracting a supplier for medical grade nanoparticles enables sponsors to leverage new technologies (available with the service provider) , access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers and technology providers, who claim to have the required capabilities to manufacture nanoparticles (lipid and metal nanoparticles) . However, the global expertise and capabilities necessary for the production of GMP grade nanoparticles are currently limited. As a result, many companies offering contract manufacturing services for nanoparticles are actively trying to consolidate their presence in this field, by entering into various strategic alliances to broaden their respective service portfolios. It is also worth highlight that, recently, a number of deals were inked between vaccine developers and CMOs in order to cater the urgent need for nanoparticle-based solutions for the development of COVID-19 vaccines. Given the benefits of using nanoparticles to improve drug-like properties, we believe, that the demand for high quality nanoparticles is likely to drive considerable growth within the specialty contract manufacturing market in the coming years.

Scope of the Report

The "Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size (Very Small Companies, Small Companies, Mid-Sized Companies, and Large Companies), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA), Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035" report features an extensive study of contract service providers engaged in manufacturing of nanoparticles for the purpose of preclinical development, clinical research and commercialization. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed overview of the current market landscape of nanoparticle contract manufacturers, along with information on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large) , location of headquarters, type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles) , location and number of manufacturing facilities, scale of operation (preclinical, clinical, and commercial) , type of end user (educational institutions, pharmaceutical companies. research institutions, and other end users) , type of service(s) offered, quality certifications and regulatory bodies.
  • An in-depth analysis, highlighting the contemporary market trends using six schematic representations, including [A] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [B] a bubble representation based on company size and type of organization, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain, [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of service(s) offered), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and type of service(s) offered).
  • An in-depth company competitiveness analysis of nanoparticle contract manufacturers, based on several relevant parameters, such as company's service strength (taking into consideration years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and type of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement) .
  • Elaborate profiles of key players that offer contract manufacturing services for nanoparticle(s). Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
  • An analysis of recent partnerships inked between various stakeholders engaged in this domain, during the period 2015-2021, based on several relevant parameters, such as year of partnership, type of partnership (company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements) , type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement and regional distribution.
  • An insightful analysis, highlighting the various factors that need to be taken into consideration by nanoparticle(s) developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the nanoparticle contract manufacturing market over the next fourteen years. We have also provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, over the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large) , [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles) , [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users) , and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world) . In order to account for future uncertainties in the market and add robustness to our forecast model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market's evolution. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players involved in nanoparticle contract manufacturing?
  • Which global regions are considered as key hubs for contract manufacturing of nanoparticles?
  • What are the most common services offered by nanoparticle contract manufacturers?
  • What type of partnership models are commonly adopted by stakeholders engaged in this industry?
  • Which factors are likely to influence the decision of nanoparticle manufacturing being done in-house or outsourced?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the likely evolution of the nanoparticle contract manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction on nanoparticles, along with information on various types and applications of nanoparticles in the pharmaceutical industry. Additionally, it includes information on the various challenges associated with manufacturing of nanoparticles. Further, it features a brief discussion on the growing need for outsourcing within this domain.

Chapter 4 provides a detailed review of the overall landscape of nanoparticle contract manufacturing landscape. It includes information of over 50 contract manufacturers currently engaged in the domain of nanoparticle contract manufacturing. Additionally, it features an in-depth analysis of service providers, based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters (region-wise), type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of nanoparticle manufacturing facilities, scale of operation (preclinical, clinical and commercial), type of end user (educational institutions, pharmaceutical companies, research institutions and other end users), quality certifications, regulatory organizations and include details on type of services offered (analytical method development, fill / finish and packaging, formulation development, manufacturing, method qualification and sustainability, process development / pre-formulation, scale-up, stability studies, and other services).

Chapter 5 highlights the contemporary market trends in six schematic representations, which include [A] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [B] a bubble representation based on company size and type of organization, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain, [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of services offered,), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and types of service(s) offered).

Chapter 6 features a detailed company competitiveness analysis of the nanoparticle contract manufacturers, of very small, small, mid-sized and large companies, based on several relevant parameters, such as company's service strength (taking into consideration a number of parameters, such as years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and types of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).

Chapter 7 provides detailed profiles of the key players (shortlisted based on a proprietary criterion) that are active in the nanoparticle contract manufacturing market. Each profile provides an overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, details on recent developments, as well as an informed future outlook.

Chapter 8 features an analysis of recent collaborations and partnerships that have been inked between several stakeholders engaged in this domain, during the period 2015-2021. It includes a brief description of the partnership models (including company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements) adopted by various stakeholders in the domain of nanoparticle contract manufacturing. Further, it comprises of analysis based on the year of partnership, type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement. Further, the chapter includes a world map representation of all the deals inked in this field in the period 2015-2021, highlighting both intercontinental and intracontinental partnership activity.

Chapter 9 presents an insightful analysis that highlights the various factors that need to be taken into consideration by nanoparticle-based therapeutics developers, while deciding whether to manufacture their respective therapeutics in-house or engage the services of a CMOs. Further, the analysis highlights all the key parameters that must be considered by players of different company sizes (very small, small, mid-sized, and large) while taking the aforementioned decision.

Chapter 10 features a comprehensive market forecast analysis, highlighting the likely growth of the nanoparticle contract manufacturing market, for the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world).

Chapter 11 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations, which are engaged in the domain of nanoparticle contract manufacturing. In this chapter, we have presented the details of our conversation with Asha Van Rooijen and Bart Metselaar (Founder and Chief Executive Officer, Director, Research and Development, LIPOSOMA).

Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Nanoparticles
    • 3.2.1. Type of Nanoparticle(s)
  • 3.3. Challenges Associated with Manufacturing of Nanoparticles
  • 3.4 Overview of Contract Manufacturing
  • 3.4.1 Commonly Outsourced Nanoparticle Manufacturing Operations
  • 3.5. Advantages of Outsourcing Nanoparticle Manufacturing Operations
  • 3.6. Key Considerations while Selecting a Contract Manufacturing Partner
  • 3.7. Future Perspective

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Nanoparticle Contract Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Type of Organization
    • 4.2.5. Analysis by Type of Nanoparticle(s) Manufactured
    • 4.2.6. Analysis by Location of Manufacturing Facilities
    • 4.2.7. Analysis by Scale of Operation
    • 4.2.8. Analysis by Type of End User
    • 4.2.9. Analysis by Type of Service(s) Offered
    • 4.2.10. Analysis by Quality Certifications
    • 4.2.11. Analysis by Regulatory Bodies
    • 4.2.12. Leading Nanoparticle Contract Manufacturers: Analysis by Number of Manufacturing Facilities

5. KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. Analysis by Company Size and Type of Organization
  • 5.3. Analysis by Company Size and Type of Nanoparticle(s) Manufactured
  • 5.4. Analysis by Company Size and Scale of Operation
  • 5.5. Analysis by Location of Headquarters (Country-wise)
  • 5.6. Analysis by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Services Offered (4D Bubble Representation)
  • 5.7. Analysis by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, Type of Service(s) Offered (Grid Representation)

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Assumptions and Key Parameters
  • 6.3. Methodology
  • 6.4. Benchmarking of Service Strength
  • 6.5. Benchmarking of Partnership Activity
  • 6.6. Nanoparticle Contract Manufacturers: Company Competitiveness Analysis
    • 6.6.1. Company Competitiveness Analysis: Very Small Companies
    • 6.6.2. Company Competitiveness Analysis: Small Companies
    • 6.6.3. Company Competitiveness Analysis: Mid-Sized Companies
    • 6.6.4. Company Competitiveness Analysis: Large Companies

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Ardena
    • 7.2.1. Company Overview
    • 7.2.2. Recent Developments and Future Outlook
  • 7.3. Curia
    • 7.3.1. Company Overview
    • 7.3.2. Recent Developments and Future Outlook
  • 7.4. Corden Pharma
    • 7.4.1. Company Overview
    • 7.4.2. Recent Developments and Future Outlook
  • 7.5. Evonik
    • 7.5.1. Company Overview
    • 7.5.2. Recent Developments and Future Outlook
  • 7.6. LSNE Contract Manufacturing
    • 7.6.1. Company Overview
    • 7.6.2. Recent Developments and Future Outlook
  • 7.7. Polymun
    • 7.7.1. Company Overview
    • 7.7.2. Recent Developments and Future Outlook
  • 7.8. TechNanoIndia
    • 7.8.1. Company Overview
    • 7.8.2. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Nanoparticle Contract Manufacturing: Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Type of Partner
    • 8.3.4. Analysis by Type of Nanoparticle(s) Manufactured
    • 8.3.5. Emerging Focus Areas
    • 8.3.6. Analysis by Seniority Level of Stakeholders
    • 8.3.7. Most Active Players: Analysis by Number of Partnerships
    • 8.3.8. Analysis by Geography
      • 8.3.8.1. Region-wise Distribution
      • 8.3.8.2. Country-wise Distribution

9. OUTSOURCING: GO / NO-GO FRAMEWORK

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Parameter Definitions
  • 9.3. Nanoparticle-based Therapeutics Developers Outsourcing: Go / No-Go Framework
    • 9.3.1. Scenario 1
    • 9.3.2. Scenario 2
    • 9.3.3. Scenario 3
    • 9.3.4. Scenario 4
    • 9.3.5. Scenario 5
  • 9.4. Outsourcing: Go / No-Go Framework
    • 9.4.1. Very Small Companies
    • 9.4.2. Small Companies
    • 9.4.3. Mid-Sized Companies
    • 9.4.4. Large Companies
  • 9.5. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology and Key Assumptions
  • 10.3. Global Nanoparticle Contract Manufacturing Market, 2021-2035
  • 10.4. Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
    • 10.4.1. Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035
    • 10.4.2. Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035
    • 10.4.3. Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035
    • 10.4.4. Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035
  • 10.5. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
    • 10.5.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035
    • 10.5.2. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035
  • 10.6. Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
    • 10.6.1. Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035
    • 10.6.2. Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035
    • 10.6.3. Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035
  • 10.7. Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
    • 10.7.1. Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035
    • 10.7.2. Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035
    • 10.7.3. Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035
    • 10.7.4. Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035
  • 10.8. Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
    • 10.8.1. Nanoparticle Contract Manufacturing Market in North America, 2021-2035
    • 10.8.2. Nanoparticle Contract Manufacturing Market in Europe, 2021-2035
    • 10.8.3. Nanoparticle Contract Manufacturing Market in Asia, 2021-2035
    • 10.8.4. Nanoparticle Contract Manufacturing Market in MENA, 2021-2035
    • 10.8.5. Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035
    • 10.8.6. Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035
  • 10.9. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle and Region, 2021 and 2035
    • 10.9.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035
    • 10.9.2. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035
    • 10.9.3. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035
    • 10.9.4. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035
    • 10.9.5. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035
    • 10.9.6. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035
    • 10.9.7. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035
    • 10.9.8. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035
    • 10.9.9. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035
    • 10.9.10. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA,2021-2035
    • 10.9.11. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035
    • 10.9.12. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. LIPOSOMA
    • 12.2.1. Company Snapshot
    • 12.2.2. Interview Transcript: Asha Van Rooijen, Founder and Chief Executive Officer, Bart Metselaar, Director, Research and Development

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

  • Figure 3.1 Application of Nanoparticles in Healthcare
  • Figure 3.2 Type of Nanoparticle(s) Based on Source of Material
  • Figure 3.3 Challenges Associated with Manufacturing of Nanoparticles
  • Figure 3.4 Type of the Third- Party Service Provider(s)
  • Figure 3.5 Commonly Outsourced Nanoparticle Manufacturing Operations
  • Figure 4.1 Nanoparticle Contract Manufactures: Distribution by Year of Establishment
  • Figure 4.2 Nanoparticle Contract Manufactures: Distribution by Company Size
  • Figure 4.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
  • Figure 4.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
  • Figure 4.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
  • Figure 4.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
  • Figure 4.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
  • Figure 4.8 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters (Country-wise) and Type of Nanoparticle(s) Manufactured
  • Figure 4.9 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
  • Figure 4.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
  • Figure 4.11 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-wise)
  • Figure 4.12 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
  • Figure 4.13 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
  • Figure 4.14 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
  • Figure 4.15 Nanoparticle Contract Manufactures: Distribution by Type of End User
  • Figure 4.16 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End User
  • Figure 4.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End User
  • Figure 4.18 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
  • Figure 4.19 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
  • Figure 4.20 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
  • Figure 4.21 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
  • Figure 4.22 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
  • Figure 5.1 Key Insights: Distribution by Company Size and Type of Organization
  • Figure 5.2 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
  • Figure 5.3 Key Insights: Distribution by Company Size and Scale of Operation
  • Figure 5.4 Key Insights: Distribution by Location of Headquarters (Country-wise)
  • Figure 5.5 4D Bubble Representation: Distribution by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Service(s) Offered
  • Figure 5.6 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, and Type of Service(s) Offered
  • Figure 6.1 Nanoparticle Contract Manufacturers: Benchmarking of Service Strength
  • Figure 6.2 Nanoparticle Contract Manufacturers: Benchmarking of Partnership Activity
  • Figure 6.3 Company Competitiveness Analysis: Very Small Companies
  • Figure 6.4 Company Competitiveness Analysis: Small Companies
  • Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
  • Figure 6.6 Company Competitiveness Analysis: Large Companies
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 8.6 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
  • Figure 8.7 Partnerships and Collaborations: Emerging Focus Area
  • Figure 8.8 Partnerships and Collaborations: Distribution by Seniority Level of Stakeholders
  • Figure 8.9 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.10 Partnerships and Collaborations: Distribution by Geography
  • Figure 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 Outsourcing: Go / No-Go Framework
  • Figure 9.2 Outsourcing: Go / No-Go Framework: Benchmarking Leading Players
  • Figure 10.1 Global Nanoparticle Contract Manufacturing Market, 2021-2035 (USD Billion)
  • Figure 10.2 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
  • Figure 10.3 Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035 (USD Billion)
  • Figure 10.4 Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 (USD Billion)
  • Figure 10.5 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035 (USD Billion)
  • Figure 10.6 Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 (USD Billion)
  • Figure 10.7 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
  • Figure 10.8 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 (USD Billion)
  • Figure 10.9 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035 (USD Billion)
  • Figure 10.10 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
  • Figure 10.11 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 (USD Billion)
  • Figure 10.12 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 (USD Billion)
  • Figure 10.13 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 (USD Billion)
  • Figure 10.14 Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
  • Figure 10.15 Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035 (USD Billion)
  • Figure 10.16 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 (USD Billion)
  • Figure 10.17 Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035 (USD Billion)
  • Figure 10.18 Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035 (USD Billion)
  • Figure 10.19 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
  • Figure 10.20 Nanoparticle Contract Manufacturing Market in North America, 2021-2035 (USD Billion)
  • Figure 10.21 Nanoparticle Contract Manufacturing Market in Europe, 2021-2035 (USD Billion)
  • Figure 10.22 Nanoparticle Contract Manufacturing Market in Asia, 2021-2035 (USD Billion)
  • Figure 10.23 Nanoparticle Contract Manufacturing Market in MENA, 2021-2035 (USD Billion)
  • Figure 10.24 Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035 (USD Billion)
  • Figure 10.25 Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035 (USD Billion)
  • Figure 10.26 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured and Region, 2021 and 2035
  • Figure 10.27 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035 (USD Billion)
  • Figure 10.28 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035 (USD Billion)
  • Figure 10.29 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035 (USD Billion)
  • Figure 10.30 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035 (USD Billion)
  • Figure 10.31 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035 (USD Billion)
  • Figure 10.32 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
  • Figure 10.33 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035 (USD Billion)
  • Figure 10.34 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035 (USD Billion)
  • Figure 10.35 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035 (USD Billion)
  • Figure 10.36 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035 (USD Billion)
  • Figure 10.37 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035 (USD Billion)
  • Figure 10.38 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
  • Figure 12.1 Concluding Remarks: Market Landscape
  • Figure 12.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 12.3 Concluding Remarks: Market Forecast

List Of Tables

  • Table 3.1 Application of Nanoparticles in Healthcare
  • Table 3.2 Type of Nanoparticle(s) Based on Source of Material
  • Table 3.3 Challenges Associated with Manufacturing of Nanoparticles
  • Table 3.4 Type of the Third- Party Service Provider(s)
  • Table 3.5 Commonly Outsourced Nanoparticle Manufacturing Operations
  • Table 4.1 Nanoparticle Contract Manufactures: Distribution by Year of Establishment
  • Table 4.2 Nanoparticle Contract Manufactures: Distribution by Company Size
  • Table 4.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
  • Table 4.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
  • Table 4.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
  • Table 4.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
  • Table 4.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
  • Table 4.8 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters (Country-wise) and Type of Nanoparticle(s) Manufactured
  • Table 4.9 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
  • Table 4.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
  • Table 4.11 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-wise)
  • Table 4.12 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
  • Table 4.13 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
  • Table 4.14 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
  • Table 4.15 Nanoparticle Contract Manufactures: Distribution by Type of End User
  • Table 4.16 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End User
  • Table 4.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End User
  • Table 4.18 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
  • Table 4.19 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
  • Table 4.20 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
  • Table 4.21 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
  • Table 4.22 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
  • Table 5.1 Key Insights: Distribution by Company Size and Type of Organization
  • Table 5.2 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
  • Table 5.3 Key Insights: Distribution by Company Size and Scale of Operation
  • Table 5.4 Key Insights: Distribution by Location of Headquarters (Country-wise)
  • Table 5.5 4D Bubble Representation: Distribution by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Service(s) Offered
  • Table 5.6 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, and Type of Service(s) Offered
  • Table 6.1 Nanoparticle Contract Manufacturers: Benchmarking of Service Strength
  • Table 6.2 Nanoparticle Contract Manufacturers: Benchmarking of Partnership Activity
  • Table 6.3 Company Competitiveness Analysis: Very Small Companies
  • Table 6.4 Company Competitiveness Analysis: Small Companies
  • Table 6.5 Company Competitiveness Analysis: Mid-sized Companies
  • Table 6.6 Company Competitiveness Analysis: Large Companies
  • Table 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
  • Table 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 8.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
  • Table 8.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 8.6 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
  • Table 8.7 Partnerships and Collaborations: Emerging Focus Area
  • Table 8.8 Partnerships and Collaborations: Distribution by Seniority Level of Stakeholders
  • Table 8.9 Most Active Players: Distribution by Number of Partnerships
  • Table 8.10 Partnerships and Collaborations: Distribution by Geography
  • Table 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 9.1 Outsourcing: Go / No-Go Framework
  • Table 9.2 Outsourcing: Go / No-Go Framework: Benchmarking Leading Players
  • Table 10.1 Global Nanoparticle Contract Manufacturing Market, 2021-2035 (USD Billion)
  • Table 10.2 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
  • Table 10.3 Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035 (USD Billion)
  • Table 10.4 Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 (USD Billion)
  • Table 10.5 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035 (USD Billion)
  • Table 10.6 Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 (USD Billion)
  • Table 10.7 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
  • Table 10.8 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 (USD Billion)
  • Table 10.9 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035 (USD Billion)
  • Table 10.10 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
  • Table 10.11 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 (USD Billion)
  • Table 10.12 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 (USD Billion)
  • Table 10.13 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 (USD Billion)
  • Table 10.14 Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
  • Table 10.15 Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035 (USD Billion)
  • Table 10.16 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 (USD Billion)
  • Table 10.17 Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035 (USD Billion)
  • Table 10.18 Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035 (USD Billion)
  • Table 10.19 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
  • Table 10.20 Nanoparticle Contract Manufacturing Market in North America, 2021-2035 (USD Billion)
  • Table 10.21 Nanoparticle Contract Manufacturing Market in Europe, 2021-2035 (USD Billion)
  • Table 10.22 Nanoparticle Contract Manufacturing Market in Asia, 2021-2035 (USD Billion)
  • Table 10.23 Nanoparticle Contract Manufacturing Market in MENA, 2021-2035 (USD Billion)
  • Table 10.24 Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035 (USD Billion)
  • Table 10.25 Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035 (USD Billion)
  • Table 10.26 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured and Region, 2021 and 2035
  • Table 10.27 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035 (USD Billion)
  • Table 10.28 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035 (USD Billion)
  • Table 10.29 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035 (USD Billion)
  • Table 10.30 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035 (USD Billion)
  • Table 10.31 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035 (USD Billion)
  • Table 10.32 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
  • Table 10.33 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035 (USD Billion)
  • Table 10.34 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035 (USD Billion)
  • Table 10.35 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035 (USD Billion)
  • Table 10.36 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035 (USD Billion)
  • Table 10.37 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035 (USD Billion)
  • Table 10.38 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (USD Billion)
  • Table 12.1 Concluding Remarks: Market Landscape
  • Table 12.2 Concluding Remarks: Partnerships and Collaborations
  • Table 12.3 Concluding Remarks: Market Forecast

List Of Companies

  • 1. Ajinomoto Bio-Pharma Services
  • 2. Alfa Aesar
  • 3. Amplicon Biotech
  • 4. Applied Chemical Works
  • 5. Arcturus Therapeutics
  • 6. Ardena
  • 7. Ascendia Pharmaceuticals
  • 8. AstraZeneca
  • 9. AVANSA Technology & Services
  • 10. Avanti Polar Lipids
  • 11. Axolabs
  • 12. BASF
  • 13. BBI Group
  • 14. BioNTech
  • 15. BIOZOL Diagnostica
  • 16. BOC Sciences
  • 17. Caisson Biotech
  • 18. Cal Nano
  • 19. Cambridge Nanomaterials Technology
  • 20. CanSinoBIO
  • 21. Cayman Chemical
  • 22. CONTRACTOR BUSINESS CENTER
  • 23. Celonic
  • 24. Center for Applied Nanotechnology
  • 25. Cerion
  • 26. ChemConnection
  • 27. CliniSciences
  • 28. CordenPharma
  • 29. Creative Biolabs
  • 30. Croda
  • 31. Crystallics
  • 32. CureVac
  • 33. Curia
  • 34. CYBERNANO
  • 35. Cytodiagnostics
  • 36. Daiichi Sankyo
  • 37. Danaher
  • 38. DCN Dx
  • 39. Deakin University
  • 40. Dolomite Microfluidics
  • 41. E.M. Sullivan Associates
  • 42. Eikonix
  • 43. EMJapan
  • 44. Encapsula NanoSciences
  • 45. Entos
  • 46. European Commission
  • 47. Evonik
  • 48. Exelead
  • 49. Fortis Life Sciences
  • 50. FUJIFILM Holdings
  • 51. GHO Capital
  • 52. Howei Pharm
  • 53. Hongwu International Group
  • 54. i-DNA Biotechnology
  • 55. Idifarma
  • 56. Integrity Bio
  • 57. Larodan
  • 58. LEON
  • 59. LIPOSOMA
  • 60. LSNE Contract Manufacturing
  • 61. Meliorum Technologies
  • 62. Molchem Technologies UK
  • 63. MyBiotech
  • 64. Nagase Medicals
  • 65. Nanochemazone
  • 66. nanoComposix
  • 67. Nanocs
  • 68. NanoHybrids
  • 69. NanoMaterials Technology
  • 70. Nanomics Technologies
  • 71. Nanophase Technologies
  • 72. Nanoshel
  • 73. Nanostructured & Amorphous Materials
  • 74. NARD Institute
  • 75. NNCrystal
  • 76. Novo Holdings
  • 77. Nucleus Medical Media
  • 78. NVIGEN
  • 79. NYACOL® Nano Technologies
  • 80. Ocean NanoTech
  • 81. Osaka University
  • 82. Permira
  • 83. Pfizer
  • 84. Pharmavize
  • 85. Phosphorex
  • 86. Polymun
  • 87. Precision NanoSystems
  • 88. Pró-Análise
  • 89. Prodotti Gianni
  • 90. Santhiram Chemicals
  • 91. Seashell Technology
  • 92. Shionogi
  • 93. Sirnaomics
  • 94. SkySpring Nanomaterials
  • 95. Stanipharm
  • 96. Stratech Scientific
  • 97. Strem
  • 98. Syntagon
  • 99. T&T Scientific
  • 100. TechNanoIndia
  • 101. The Energy and Resources Institute (TERI)
  • 102. U.S. Army
  • 103. Vaxinano
  • 104. Veritas Technologies
  • 105. ZoneOne Pharma